CARDIFF ONCOLOGY INC's ticker is CRDF and the CUSIP is 14147L108. A total of 93 filers reported holding CARDIFF ONCOLOGY INC in Q1 2022. The put-call ratio across all filers is 1.69 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $113,642 | -58.4% | 51,190 | 0.0% | 0.00% | -100.0% |
| Q1 2024 | $273,355 | +260.8% | 51,190 | 0.0% | 0.00% | – |
| Q4 2023 | $75,761 | +6.5% | 51,190 | 0.0% | 0.00% | – |
| Q3 2023 | $71,154 | -5.4% | 51,190 | 0.0% | 0.00% | – |
| Q2 2023 | $75,249 | -10.9% | 51,190 | 0.0% | 0.00% | – |
| Q1 2023 | $84,464 | +17.9% | 51,190 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $71,666 | -9.3% | 51,190 | 0.0% | 0.00% | – |
| Q3 2022 | $79,000 | -30.1% | 51,190 | 0.0% | 0.00% | -100.0% |
| Q2 2022 | $113,000 | -11.0% | 51,190 | 0.0% | 0.00% | – |
| Q1 2022 | $127,000 | -58.8% | 51,190 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $308,000 | -11.7% | 51,190 | -2.2% | 0.00% | 0.0% |
| Q3 2021 | $349,000 | +2.6% | 52,349 | +2.3% | 0.00% | 0.0% |
| Q2 2021 | $340,000 | -35.8% | 51,190 | -10.5% | 0.00% | -50.0% |
| Q1 2021 | $530,000 | -76.4% | 57,220 | -54.1% | 0.00% | -75.0% |
| Q4 2020 | $2,245,000 | – | 124,788 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 2,114,840 | $38,046,000 | 23.72% |
| Corriente Advisors, LLC | 2,000,000 | $35,980,000 | 8.56% |
| Octagon Capital Advisors LP | 650,000 | $11,694,000 | 4.05% |
| Opaleye Management Inc. | 1,662,500 | $29,908,000 | 3.91% |
| Altium Capital Management LP | 185,552 | $3,338,000 | 1.25% |
| Tri Locum Partners LP | 157,403 | $2,832,000 | 1.03% |
| Avidity Partners Management LP | 1,607,000 | $28,910,000 | 0.94% |
| RA Capital Management | 3,290,000 | $59,187,000 | 0.83% |
| FRAZIER MANAGEMENT LLC | 568,500 | $10,227,000 | 0.79% |
| Sio Capital Management, LLC | 149,833 | $2,695,000 | 0.55% |